ArticleOncotarget2017

Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01).

Hye Ryun Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.